Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover which HYD ETF fits best for retirement planning with an eye on income stability and diversification. Learn key factors to compare and start building a resilient retirement portfolio.
22,439 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
AI is reshaping markets faster than many investors expect. This no-brainer artificial intelligence (AI) stock story b...
A leading AI company hints at a monumental goal: $9 trillion in market value. We explore what that could mean for inv...
Palantir delivered an 85% year-over-year revenue surge in Q1 2026 and lifted full-year targets, but the shares are do...
Solana and Google Cloud have launched Pay.sh, a pay-as-you-go gateway that enables AI agents to purchase API access w...
Federal investigators say UCLA's David Geffen School of Medicine used race in admissions in ways that violated civil ...
A former antitrust prosecutor who helped litigate the JetBlue-Spirit merger shares lessons for future airline regulat...
Qualcomm is trading at a discount to peers while building a strong AI silicon footprint. With a June Investor Day and...
Stripe's Patrick Collison warns a surge in token theft is upending the AI startup landscape, forcing changes to free ...
This article dives into EverCommerce (evcm) 2026 earnings, unpacking Q1 results, growth drivers, and the implications...
A celebrity legal shock isn’t just a headline—it can ripple through finances. This article breaks down practical step...
A fictional scenario inspired by a viral moment shows how public posts can ripple into real financial consequences. T...